Sverige - svenska - Läkemedelsverket (Medical Products Agency)

wirtschaftsgenossenschaft deutscher tierarzte (wdt) eg - bensylpenicillinprokainmonohydrat - intramammär suspension - 3 g - natriummetabisulfit hjälpämne; bensylpenicillinprokainmonohydrat 3 g aktiv substans - nöt

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

wirtschaftsgenossenschaft deutscher tierarzte (wdt) eg - propentofyllin - filmdragerad tablett - 50 mg - laktosmonohydrat hjälpämne; propentofyllin 50 mg aktiv substans - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

wirtschaftsgenossenschaft deutscher tierarzte (wdt) eg - propentofyllin - filmdragerad tablett - 100 mg - laktosmonohydrat hjälpämne; propentofyllin 100 mg aktiv substans - hund

Europeiska unionen - svenska - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatid - osteoporos - calciumhomeostas - movymia indikeras hos vuxna. behandling av osteoporos hos postmenopausala kvinnor och hos män med ökad risk för fraktur. hos postmenopausala kvinnor, har en betydande minskning i incidensen av vertebrala och icke kotfrakturer men inte höftfrakturer visats. behandling av osteoporos i samband med ihållande systemisk glukokortikoid behandlingen för kvinnor och män med ökad risk för fraktur.

Europeiska unionen - svenska - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, tarm -, antiinflammatoriska / antiinfective agenter - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Europeiska unionen - svenska - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ögonsjukdomar - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europeiska unionen - svenska - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiska medel - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. för vidare information om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. för ytterligare information om her2-status, se avsnitt 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

floris holding b.v. - acepromazinmaleat - oral gel - 35 mg/ml - acepromazinmaleat 47,5 mg aktiv substans; glycerol hjälpämne; propylparahydroxibensoat hjälpämne; metylparahydroxibensoat hjälpämne - acepromazin - häst

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

elanco animal health gmbh - enrofloxacin - injektionsvätska, lösning - 25 mg/ml - enrofloxacin 25 mg aktiv substans - enrofloxacin - burfåglar, gnagare, hund, kanin, katt, reptiler, svin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

cogmill pharma ab - ferroglycinsulfatkomplex - orala droppar, lösning - 30 mg/ml - ferroglycinsulfatkomplex 170 mg aktiv substans; sorbitol hjälpämne - järn(ii)glycinsulfat